Therefore, future large‐scale prospective studies are needed to investigate the dynamic changes in SII during AD progression and treatment, particularly its interactions with emerging biomarkers (e.g., IgE and IL‐13), thereby refining personalized treatment algorithms. The gene discussed is IGHE; the disease is Alzheimer disease.